Australian Toll Road Projects Have Investment-Grade Potential Aug 02

  • ID: 2091467
  • August 2002
  • Region: Australia
  • Standard & Poors
1 of 3

MELBOURNE (Standard & Poor's) Aug. 29, 2002--Standard & Poor's today highlighted the relative success of the Australian toll-road sector while releasing its in-house research that identifies and quantifies the pitfalls affecting traffic forecasts of toll-road projects. Through the study, based on the review of 32 toll facilities in the U.S., the U.K., and Asia, Standard & Poor's has developed an analytical tool-the Traffic Risk Index-to assist in interpreting traffic forecasts and the uncertainty that may surround a start-up toll road. With three greenfield toll roads slated for construction in Sydney in the next year or two, the study provides valuable insights to financiers and investors alike in identifying the risks in forecasting traffic trends. "Relative to global trends, the privately...

Companies mentioned in this report are: Australia (Commonwealth of) (Unsolicited Ratings)
Action: S&P Event

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Australia (Commonwealth of) (Unsolicited Ratings)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.